Structure-based drug design to overcome drug resistance: Challenges and opportunities

Current Pharmaceutical Design

Volumn 20, Issue 5, 2014, Pages 687-693

  Ferreira, Rafaela S ^a   Andricopulo, Adriano D ^b  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Drug discovery; Drug resistance; Structure based drug design; Therapeutic agents

Indexed keywords

PROTEIN;

DRUG DESIGN; DRUG MECHANISM; DRUG RESISTANCE; DRUG STRUCTURE; HUMAN; INHIBITION KINETICS; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW;

ANIMALS; DRUG DESIGN; DRUG RESISTANCE; DRUG RESISTANCE, MULTIPLE; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR TARGETED THERAPY; MUTANT PROTEINS; PHARMACOLOGY;

EID: 84895124066     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161282005140214161949     Document Type: Review

References (91)

1. Wright GD. Antibiotics: A new hope. Chem Biol 2012; 19: 3-10.
2. Anderson AC, Pollastri MP, Schiffer CA, Peet NP. The challenge of developing robust drugs to overcome resistance. Drug Discov Today 2011; 16: 755-61.
3. Nikaido H, Pages J-M. Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria. Fems Microbiol Rev 2012; 36: 340-63.
4. Strahilevitz J, Jacoby GA, Hooper DC, Robicsek A. Plasmidmediated quinolone eesistance: a multifaceted threat. Clin Microbiol Rev 2009; 22: 664
5. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117-25.
6. Drawz SM, Bonomo RA. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev 2010; 23: 160-201.
7. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399-401.
8. Kolb P, Ferreira RS, Irwin JJ, Shoichet BK. Docking and chemoinformatic screens for new ligands and targets. Curr Opin Biotechnol 2009; 20: 429-36.
9. Mascarello A, Chiaradia LD, Vernal J, et al. Inhibition of Mycobacterium tuberculosis tyrosine phosphatase PtpA by synthetic chalcones: Kinetics, molecular modeling, toxicity and effect on growt. Bioorg Med Chem 2010; 18: 3783-9.
10. Ferreira RS, Guido RVC, Andricopulo AD, Oliva G. In silico screening strategies for novel inhibitors of parasitic diseases. Expert Opin Drug Dis 2011; 6: 481-9.
11. Murray CW, Carr MG, Callaghan O, et al. Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency. J Med Chem 2010; 53: 5942-55.
12. Bryant C, Kerr ID, Debnath M, et al. Novel non-peptidic vinylsulfones targeting the S2 and S3 subsites of parasite cysteine proteases. Bioorg Med Chem Lett 2009; 19: 6218-21.
13. Castilho MS, Postigo MP, Pereira HM, Oliva G, Andricopulo AD. Structural basis for selective inhibition of purine nucleoside phosphorylase from Schistosoma mansoni: Kinetic and structural studies. Bioorg Med Chem 2011, 18: 1421-7.
14. Postigo MP, Guido RVC, Oliva G, et al. Discovery of new inhibitors of Schistosoma mansoni PNP by pharmacophore-based virtual screening. J Chem Inf Model 2010; 50: 1693-705.
15. Teotico DG, Babaoglu K, Rocklin GJ, Ferreira RS, Giannetti AM, Shoichet BK. Docking for fragment inhibitors of AmpC betalactamase. Proc Natl Acad Sci USA 2009; 106: 7455-60.
16. Ferreira RS, Simeonov A, Jadhav A, et al. Complementarity between a docking and a high-throughput screen in discovering new cruzain inhibitors. J Med Chem 2010; 53: 4891-905.
17. Woodhead AJ, Angove H, Carr MG, et al. Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design. J Med Chem 2010; 53: 5956-69.
18. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129-41.
19. Ide K, Aoki M, Amano M, et al. Novel HIV-1 protease inhibitors (PIs) containing a bicyclic P2 functional moiety, tetrahydropyranotetrahydrofuran, that are potent against multi-PI-resistant HIV-1 variants. Antimicrob Agents Ch 2011; 55: 1717-27.
20. Frey KM, Liu J, Lombardo MN, Bolstad DB, Wright DL, Anderson AC. Crystal structures of wild-type and mutant methicillin-resistant Staphylococcus aureus dihydrofolate reductase reveal an alternate conformation of NADPH that may be linked to trimethoprim resistance. J Mol Biol 2009; 387: 1298-308.
21. Frey KM, Lombardo MN, Wright DL, Anderson AC. Towards the understanding of resistance mechanisms in clinically isolated trimethoprim-resistant, methicillin-resistant Staphylococcus aureus dihydrofolate reductase. J Struct Biol 2010; 170: 93-7.
22. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-80.
23. Cowan-Jacob SW, Fendrich G, Floersheimer A, et al. Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia. Acta Crystallogr D 2007; 63: 80-93.
24. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007; 7: 345-U5.
25. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 2000; 289: 1938-42.
26. Quintas-Cardama A, Kantarjian H, Cortes J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 2007; 6: 834-48.
27. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005; 65: 4500-5.
28. Jabbour E, Cortes J, Kantarjian H. Long-term outcomes in the second-line treatment of chronic myeloid leukemia: A review of tyrosine kinase inhibitors. Cancer 2011; 117: 897-906.
29. Kantarjian HM, Hochhaus A, Saglio G. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial (vol 12 pg 841 2011). Lancet Oncol 2011; 12: 989-9.
30. Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman SJ. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007; 109: 500-2.
31. Young MA, Shah NP, Chao LH, et al. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the aurora kinase inhibitor VX-680. Cancer Res 2006; 66: 1007-14.
32. Traynor AM, Hewitt M, Liu G, et al. Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemoth Pharm 2011; 67: 305-14.
33. Cowan-Jacob SW, Mobitz H, Fabbro D. Structural biology contributions to tyrosine kinase drug discovery. Curr Opin Cell Biol 2009; 21: 280-7.
34. Adrian FJ, Ding Q, Sim TB, et al. Allosteric inhibitors of Bcr-abldependent cell proliferation. Nat Chem Biol 2006; 2: 95-102.
35. Zhang JM, Adrian FJ, Jahnke W, et al. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 2010; 463: 501-U116.
36. Deng XM, Okram B, Ding QA, et al. Expanding the diversity of allosteric Bcr-Abl inhibitors. J Med Chem 2010; 53: 6934-46.
37. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-m ethylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47: 6658-61.
38. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinibresistant Philadelphia chromosome-positive leukemias. New Engl J Med 2006; 354: 2531-41.
39. Tokarski JS, Newitt JA, Chang CYJ, et al. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 2006; 66: 5790-7.
40. Golas JM, Arndt K, Etienne C, et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 2003; 63: 375-81.
41. Cortes JE, Kantarjian HM, Brummendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 2011; 118: 4567-76.
42. Kimura S, Naito H, Segawa H, et al. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 2005; 106: 3948-54.
43. Horio T, Hamasaki T, Inoue T, et al. Structural factors contributing to the Abl/Lyn dual inhibitory activity of 3-substituted benzamide derivatives. Bioorg Med Chem Lett 2007; 17: 2712-7.
44. Asaki T, Sugiyama Y, Hamamoto T, et al. Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors. Bioorg Med Chem Lett 2006; 16: 1421-5.
45. Powers RA, Morandi F, Shoichet BK. Structure-based discovery of a novel, noncovalent inhibitor of AmpC beta-lactamase. Structure 2002; 10: 1013-23.
46. Chen Y, Shoichet BK. Molecular docking and ligand specificity in fragment-based inhibitor discovery. Nat Chem Biol 2009; 5: 358-64.
47. Eidam O, Romagnoli C, Caselli E, et al. Design, synthesis, crystal structures, and antimicrobial activity of sulfonamide boronic acids as beta-lactamase inhibitors. J Med Chem 2010; 53: 7852-63.
48. Morandi S, Morandi F, Caselli E, Shoichet BK, Prati F. Structure-based optimization of cephalothin-analogue boronic acids as beta-lactamase inhibitors. Bioorg Med Chem 2008; 16: 1195-205.
49. Tondi D, Powers RA, Caselli E, et al. Structure-based design and in-parallel synthesis of inhibitors of AmpC beta-lactamase. Chem Biol 2001; 8: 593-610.
50. Weston GS, Blazquez J, Baquero F, Shoichet BK. Structure-based enhancement of boronic acid-based inhibitors of AmpC beta-lactamase. J Med Chem 1998; 41: 4577-86.
51. Hubschwerlen C, Angehrn P, Gubernator K, Page MGP, Specklin JL. Structure-based design of beta-lactamase inhibitors. 2. Synthesis and evaluation of bridged sulfactams and oxamazins. J Med Chem 1998; 41: 3972-5.
52. Heinze-Krauss I, Angehrn P, Charnas RL, et al. Structure-based design of beta-lactamase inhibitors. 1. Synthesis and evaluation of bridged monobactams. J Med Chem 1998; 41: 3961-71.
53. Plantan I, Selic L, Mesar T, et al. 4-substituted trinems as broad spectrum beta-lactamase inhibitors: Structure-based design, synthesis, and biological activity. J Med Chem 2007; 50: 4113-21.
54. Tondi D, Morandi F, Bonnet R, Costi MP, Shoichet BK. Structure-based optimization of a non-beta-lactam lead results in inhibitors that do not up-regulate beta-lactamase expression in cell culture. J Am Chem Soc 2005; 127: 4632-9.
55. Hubschwerlen C, Angehrn P, Gubernator K, Page MGP, Specklin JL. Structure-based design of beta-lactamase inhibitors. 2. Synthesis and evaluation of bridged sulfactams and oxamazins. Journal of Medicinal Chemistry 1998; 41: 3972-5.
56. Copar A, Prevec T, Anzic B, et al. Design, synthesis and bioactivity evaluation of tribactam beta lactamase inhibitors. Bioorg Med Chem Lett 2002; 12: 971-5.
57. Powers RA, Blazquez J, Weston GS, Morosini MI, Baquero F, Shoichet BK. The complexed structure and antimicrobial activity of a non-beta-lactam inhibitor of AmpC beta-lactamase. Protein Sci 1999; 8: 2330-7.
58. Morandi F, Caselli E, Morandi S, et al. Nanomolar inhibitors of AmpC beta-lactamase. J Am Chem Soc 2003; 125: 685-95.
59. Tondi D, Calo S, Shoichet BK, Costi MP. Structural study of phenyl boronic acid derivatives as AmpC beta-lactamase inhibitors. Bioorg Med Chem Lett 2010; 20: 3416-9.
60. Powers RA, Morandi F, Shoichet BK. Structure-based discovery of a novel, noncovalent inhibitor of AmpC beta-lactamase. Structure 2002; 10: 1013-23.
61. Babaoglu K, Simeonov A, Irwin J, et al. A comprehensive mechanistic analysis of hits from high-throughput and docking screens against AmpC betalactamase. J Med Chem 2008; 51: 2501-11.
62. Magnet S, Blanchard JS. Molecular insights into aminoglycoside action and resistance. Chemical Reviews 2005; 105: 477-97.
63. Robicsek A, Strahilevitz J, Jacoby GA, et al. Fluoroquinolonemodifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med 2006; 12: 83-8.
64. McKay GA, Thompson PR, Wright GD. Broad-spectrum aminoglycoside phosphotransferase type-III from Enterococcus-Overexpression, purification, and substrate-specificity. Biochemistry 1994; 33: 6936-44.
65. Hon WC, McKay GA, Thompson PR, et al. Structure of an enzyme required for aminoglycoside antibiotic resistance reveals homology to eukaryotic protein kinases. Cell 1997; 89: 887-95.
66. Daigle DM, McKay GA, Wright GD. Inhibition of aminoglycoside antibiotic resistance enzymes by protein kinase inhibitors. J Biol Chem 1997; 272: 24755-8.
67. Fong DH, Xiong B, Hwang J, Berghuis AM. Crystal structures of two aminoglycoside kinases bound with a eukaryotic protein kinase inhibitor. Plos One 2011; 6.
68. Shi K, Houston DR, Berghuis AM. Crystal structures of antibiotic-bound complexes of aminoglycoside 2 -phosphotransferase IVa highlight the diversity in substrate binding modes among aminoglycoside kinases. Biochemistry 2011; 50: 6237-44.
69. Vetting MW, Park CH, Hegde SS, Jacoby GA, Hooper DC, anchard JS. Mechanistic and structural analysis of aminoglycoside N-acetyltransferase AAC(6 ')-Ib and its bifunctional, fluoroquinolone-active AAC(6 ')-Ib-cr variant. Biochemistry 2008; 47: 9825-35.
70. Wolf E, Vassilev A, Makino Y, Sali A, Nakatani Y, Burley SK. Crystal structure of a GCN5-related N-acetyltransferase: Serratia marcescens aminoglycoside 3-N-acetyltransferase. Cell 1998; 94: 439-49.
71. Toth M, Frase H, Antunes NT, Smith CA, Vakulenko SB. Crystal structure and kinetic mechanism of aminoglycoside phosphotransferase-2 -IVa. Protein Sci 2010; 19: 1565-76.
72. Fong DH, Lemke CT, Hwang JY, Xiong B, Berghuis AM. Structure of the antibiotic resistance factor spectinomycin phosphotransferase from Legionella pneumophila. J Biol Chem 2010; 285: 9545-55.
73. Nikaido H. Prevention of drug access to bacterial targets-permeability barriers and active efflux. Science 1994; 264: 382-8.
74. Zaman GJR, Flens MJ, Vanleusden MR, et al. The human multidrug resistance-associated protein MRP is a plasma-membrane drug-efflux pump. P Natl Acad Sci USA 1994; 91: 8822-6.
75. Chaudhary PM, Roninson IB. Expression and activity of Pglycoprotein, a multidrug efflux pump, in human hematopoietic stem-cells. Cell 1991; 66: 85-94.
76. Xiang QF, Wang F, Su XD, et al. Effect of BIBF 1120 on reversal of ABCB1-mediated multidrug resistance. Cell Oncol 2011; 34: 33-44.
77. Tong XZ, Wang F, Liang S, et al. Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells. Biochem Pharmacol 2012; 83: 586-97.
78. Jin W, Li Q, Lin Y, et al. Reversal of imatinib resistance in BCR-ABL-positive leukemia after inhibition of the Na+/H+ exchanger. Cancer Lett 2011; 308: 81-90.
79. Murakami S, Nakashima R, Yamashita E, Yamaguchi A. Crystal structure of bacterial multidrug efflux transporter AcrB. Nature 2002; 419: 587-93.
80. Murakami S, Nakashima R, Yamashita E, Matsumoto T, amaguchi A. Crystal structures of a multidrug transporter reveal a functionally rotating mechanism. Nature 2006; 443: 173-9.
81. Nakashima R, Sakurai K, Yamasaki S, Nishino K, Yamaguchi A. Structures of the multidrug exporter AcrB reveal a proximal multisite drug-binding pocket. Nature 2011; 480: 565-U199.
82. Chellappan S, Reddy G, Ali A, et al. Design of mutation-resistant HIV protease inhibitors with the substrate envelope hypothesis. Chem Biol Drug Des 2007; 69: 298-313.
83. King NM, Prabu-Jeyabalan M, Nalivaika EA, Wigerinck P, de Bethune MP, Schiffer CA. Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J Virol 2004; 78: 12012-21.
84. Altman MD, Ali A, Reddy G, et al. HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants. J Am Chem Soc 2008; 130: 6099-113.
85. Nalam MNL, Ali A, Altman MD, et al. Evaluating the substrate-envelope hypothesis: Structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance. J Virol 2010; 84: 5368-78.
86. Ozen A, Haliloglu T, Schiffer CA. Dynamics of preferential substrate recognition in HIV-1 protease: Redefining the substrate envelope. J Mol Biol 2011; 410: 726-44.
87. Romano KP, Ali A, Royer WE, Schiffer CA. Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. P Natl Acad Sci USA 2010; 107: 20986-91.
88. Kairys V, Gilson MK, Lather V, Schiffer CA, Fernandes MX. Toward the design of mutation-resistant enzyme inhibitors: Further evaluation of the substrate envelope hypothesis. Chem Biol Drug Des 2009; 74: 234-45.
89. Ghosh AK, Chapsal BD, Weber IT, Mitsuya H. Design of HIV protease inhibitors targeting protein backbone: An effective strategy for combating drug resistance. Accounts Chem Res 2008; 41: 78-86.
90. Lefebvre E, Schiffer CA. Resilience to resistance of HIV-1 protease inhibitors: Profile of darunavir. Aids Reviews 2008; 10: 131-42.
91. Ghosh AK, Chapsal BD, Baldridge A, et al. Design and synthesis of potent HIV-1 protease inhibitors incorporating hexahydrofuropyranol-derived high affinity P(2) ligands: Structure-activity studies and biological evaluation. J Med Chem 2011; 54: 622-34.